The drug, called Tauramox, is the first generic moxidectin injectable solution to control internal and external parasites.
The US Food and Drug Administration (FDA) has just approved Tauramox as the first generic moxidectin injectable solution indicated for "beef and nonlactating dairy cattle for the treatment and control of internal and external parasites in cattle."1
Tauramox is an antiparasitic drug that contains the same concentration of moxidectin in the same injectable dosage form as the approved brand name drug product, Cydectin, which was first approved on May 20, 2005. As with Cydectin, residues in food products derived from beef and nonlactating dairy cattle treated with Tauramox will not represent a public health concern when the product is used according to the label.1
The FDA advises that the rate of administration for Tauramox Injectable is 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight. Tauramox will now be available over the counter and supplied in a 10 mg/ml concentration in 250 and 500 mL bottles.
The FDA strongly advises that when administering Tauramox, veterinary professionals be careful to estimate the animal’s body weight as closely as possible. This is important to avoid overdosing or underdosing the animal in order to ensure each animal receives a complete dose based on a current body weight. According to the FDA, underdosing may result in ineffective treatment and encourage the development of parasite resistance.1
When administered at the correct dosage, Tauramox is effective at treating and controlling the following parasites in cattle:
For specific species, go to: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13677
This article originally appeared on dvm360.